GOSSAMER BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GOSSAMER BIO, INC. (GOSS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 63.00 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 2.12M shares, a 97.41% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 60.88M shares, a 335.97% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 674.00K shares, a 66.83% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 276.25K shares, a 19.93% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 15.99M shares, a 22.93% increase from fiscal 2024.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 13.01M shares, a 24.20% decline from fiscal 2023.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 17.16M shares, a 85.08% increase from fiscal 2022.
- GOSSAMER BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 9.27M shares, a 193.48% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 2.12M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 63.00M shares 10-Q · filed 2026-08-13 | 63.67M shares derived: sum of 3 quarters · filed 2026-08-13 | 63.95M shares derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | 60.88M shares 10-Q · filed 2026-05-15 | 61.56M shares derived: sum of 2 quarters · filed 2026-05-15 | 61.83M shares derived: sum of 3 quarters · filed 2026-05-15 | 62.91M shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | 674.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 950.25K shares derived: sum of 2 quarters · filed 2026-03-17 | 2.02M shares derived: sum of 3 quarters · filed 2026-03-17 | 15.99M shares 10-K · filed 2026-03-17 | |
| 2025-09-30 | 276.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.35M shares derived: sum of 2 quarters · filed 2025-11-05 | 15.31M shares 10-Q · filed 2025-11-05 | 15.72M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | 1.07M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 15.04M shares 10-Q · filed 2025-08-05 | 15.44M shares derived: sum of 3 quarters · filed 2026-03-17 | 15.79M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | 13.96M shares 10-Q · filed 2025-05-15 | 14.37M shares derived: sum of 2 quarters · filed 2026-03-17 | 14.71M shares derived: sum of 3 quarters · filed 2026-03-17 | 15.67M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | 404.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 749.00K shares derived: sum of 2 quarters · filed 2026-03-17 | 1.70M shares derived: sum of 3 quarters · filed 2026-03-17 | 13.01M shares 10-K · filed 2026-03-17 | |
| 2024-09-30 | 345.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.30M shares derived: sum of 2 quarters · filed 2024-11-07 | 12.60M shares 10-Q · filed 2024-11-07 | 18.11M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-06-30 | 953.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 12.26M shares 10-Q · filed 2024-08-12 | 17.77M shares derived: sum of 3 quarters · filed 2026-03-17 | 17.85M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-03-31 | 11.30M shares 10-Q · filed 2024-05-07 | 16.81M shares derived: sum of 2 quarters · filed 2026-03-17 | 16.89M shares derived: sum of 3 quarters · filed 2026-03-17 | 23.84M shares derived: sum of 4 quarters · filed 2026-03-17 | |
| 2023-12-31 | 5.51M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 5.59M shares derived: sum of 2 quarters · filed 2026-03-17 | 12.54M shares derived: sum of 3 quarters · filed 2026-03-17 | 17.16M shares 10-K · filed 2026-03-17 | |
| 2023-09-30 | 79.15K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 7.03M shares derived: sum of 2 quarters · filed 2023-11-09 | 11.65M shares 10-Q · filed 2023-11-09 | 16.47M shares derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | 6.95M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 11.57M shares 10-Q · filed 2023-08-08 | 16.39M shares derived: sum of 3 quarters · filed 2025-03-13 | 16.48M shares derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-05-05 | 750.00K shares 10-K · filed 2026-03-17 | ||||
| 2023-03-31 | 4.62M shares 10-Q · filed 2023-05-09 | 9.44M shares derived: sum of 2 quarters · filed 2025-03-13 | 9.53M shares derived: sum of 3 quarters · filed 2025-03-13 | 9.85M shares derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | 4.82M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 4.91M shares derived: sum of 2 quarters · filed 2025-03-13 | 5.23M shares derived: sum of 3 quarters · filed 2025-03-13 | 9.27M shares 10-K · filed 2025-03-13 | |
| 2022-09-30 | 88.48K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 406.56K shares derived: sum of 2 quarters · filed 2022-11-03 | 4.45M shares 10-Q · filed 2022-11-03 | 4.68M shares derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | 318.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 4.36M shares 10-Q · filed 2022-08-09 | 4.59M shares derived: sum of 3 quarters · filed 2024-03-05 | 4.93M shares derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | 4.04M shares 10-Q · filed 2022-05-10 | 4.28M shares derived: sum of 2 quarters · filed 2024-03-05 | 4.61M shares derived: sum of 3 quarters · filed 2024-03-05 | 4.98M shares derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | 235.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 567.38K shares derived: sum of 2 quarters · filed 2024-03-05 | 943.60K shares derived: sum of 3 quarters · filed 2024-03-05 | 3.16M shares 10-K · filed 2024-03-05 | |
| 2021-09-30 | 331.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 707.98K shares derived: sum of 2 quarters · filed 2021-11-08 | 2.92M shares 10-Q · filed 2021-11-08 | 3.10M shares derived: sum of 4 quarters · filed 2023-03-17 | |
| 2021-06-30 | 376.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 2.59M shares 10-Q · filed 2021-08-09 | 2.76M shares derived: sum of 3 quarters · filed 2023-03-17 | 3.39M shares derived: sum of 4 quarters · filed 2023-03-17 | |
| 2021-03-31 | 2.22M shares 10-Q · filed 2021-05-06 | 2.39M shares derived: sum of 2 quarters · filed 2023-03-17 | 3.02M shares derived: sum of 3 quarters · filed 2023-03-17 | 3.20M shares derived: sum of 4 quarters · filed 2023-03-17 | |
| 2020-12-31 | 172.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 801.15K shares derived: sum of 2 quarters · filed 2023-03-17 | 987.15K shares derived: sum of 3 quarters · filed 2023-03-17 | 2.71M shares 10-K · filed 2023-03-17 | |
| 2020-09-30 | 628.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 814.90K shares derived: sum of 2 quarters · filed 2020-11-10 | 2.54M shares 10-Q · filed 2020-11-10 | 3.29M shares derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-06-30 | 186.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | 1.91M shares 10-Q · filed 2020-08-11 | 2.66M shares derived: sum of 3 quarters · filed 2022-03-03 | 3.22M shares derived: sum of 4 quarters · filed 2022-03-03 | |
| 2020-03-31 | 1.73M shares 10-Q · filed 2020-05-12 | 2.48M shares derived: sum of 2 quarters · filed 2022-03-03 | 3.03M shares derived: sum of 3 quarters · filed 2022-03-03 | 3.53M shares derived: sum of 4 quarters · filed 2022-03-03 | |
| 2019-12-31 | 752.72K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 1.31M shares derived: sum of 2 quarters · filed 2022-03-03 | 1.80M shares derived: sum of 3 quarters · filed 2022-03-03 | 4.19M shares 10-K · filed 2022-03-03 | |
| 2019-09-30 | 556.26K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 1.05M shares derived: sum of 2 quarters · filed 2019-11-12 | 3.44M shares 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | 495.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 2.89M shares 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 2.39M shares 10-Q · filed 2019-05-14 | ||||
| 2018-12-31 | 5.14M shares 10-K · filed 2021-02-26 | ||||
| 2017-12-31 | 0.00 shares 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |